Instrumento Inactivo

Otros idiomas Vital Therapies Inc Nasdaq

Acciones

US92847R1041

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Immunic CEO Dr Daniel Vitt discusses key Q1 advances and upcoming milestones	09/05
Immunic : Q1 2024 News Release	08/05
Immunic, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Immunic: Q1 Earnings Snapshot	08/05
Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update	08/05
Immunic to Participate in Investor and Scientific Conferences in May	06/05
Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal	01/05
Immunic Announces Publication of Extended Data from Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology Neuroimmunology and Neuroinflammation	01/05
Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update	01/05
Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation	30/04
Immunic CEO Dr Daniel Vitt marks International Day of Immunology with discussion on its crucial role	29/04
Immunic to Host MS R&D Day and Participate in Investor Conferences in April	04/04
Immunic Gets US Patent Notice of Allowance For Specific Polymorph of Vidofludimus Calcium	21/03
Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month	21/03
Immunic secures key patent, boosting MS drug exclusivity and global IP strategy	21/03
Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States	20/03
Immunic to reveal promising MS treatment data in two poster presentations at ACTRIMS Forum 2024	08/03
Immunic to Participate in Investor and Scientific Conferences in March	07/03
Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024	29/02
Immunic reports successful 2023 and prepares for key 2025 milestones	22/02

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Vital Therapies Inc Nasdaq

Acciones

US92847R1041

Otros idiomas

Filtros